A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: Implications in cancer therapy

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 103-112

  Dai, Lu ^a   Liu, Yuqing ^b   Liu, Junyang ^a   Wen, Xiaoming ^a   Xu, ZhengShuang ^a,b   Wang, Zhuo ^b   Sun, Hong ^c   Tang, Shoubin ^a   Maguire, Anita R ^d   Quan, Junmin ^a   Zhang, Hui ^a,c   Ye, Tao ^a,b  

^a PEKING UNIVERSITY   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c UNIVERSITY OF NEVADA   (United States)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Apoptosis; Cell cycle; CyclinE CyclinA CDK Inhibitor; Proliferation

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; RETINOBLASTOMA PROTEIN; THREONINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME BINDING; ENZYME DEGRADATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 84876077100     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.025     Document Type: Article

References (34)

1. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
2. Graña X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995, 11:211-219.
3. Hunter T. Oncoprotein networks. Cell 1997, 88:333-346.
4. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1:222-231.
5. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68:67-108.
6. Hengst L., Dulic V., Slingerland J.M., Lees E., Reed S.I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 1994, 91:5291-5295.
7. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66.
8. Toyoshima H., Hunter T. p27, A novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74.
9. Lacy E.R., Wang Y., Post J., Nourse A., Webb W., Mapelli M., et al. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. J. Mol. Biol. 2005, 349:764-773.
10. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 1997, 3:231-234.
11. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
12. Shirane M., Harumiya Y., Ishida N., Hirai A., Miyamoto C., Hatakeyama S., et al. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 1999, 274:13886-13893.
13. Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 2000, 183:10-17.
14. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
15. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A., et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999, 13:1181-1189.
16. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997, 16:5334-5344.
17. Chu I., Sun J., Arnaout A., Kahn H., Hanna W., Narod S., et al. p27 Phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007, 128:281-294.
18. Ganoth D., Bornstein G., Ko T.K., Larsen B., Tyers M., Pagano M., et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol. 2001, 3:321-324.
19. Kip1. Mol. Cell 2001, 7:639-650.
20. Gray N., Détivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6:859-875.
21. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23:417-425.
22. Lees J.A., Weinberg R.A. Tossing monkey wrenches into the clock: new ways of treating cancer. Proc. Natl. Acad. Sci. USA 1999, 96:4221-4223.
23. Kong N., Fotouhi N., Wovkulich P.M., Roberts J. Cell cycle inhibitors for the treatment of cancer. Drugs Future 2003, 28:881-896.
24. Johnson L.N., Lewis R.J. Structural basis for control by phosphorylation. Chem. Rev. 2001, 101:2209-2242.
25. Toogood P.L. Cyclin-dependent kinase inhibitors for treating cancer. Med. Res. Rev. 2001, 21:487-498.
26. Liu Y., Wang Z., Kwong S.Q., Lui E.L., Friedman S.L., Li F.R., et al. Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J. Hepatol. 2011, 55:612-625.
27. Lacy E.R., Filippov I., Lewis W.S., Otieno S., Xiao L., Weiss S., et al. p27 Binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat. Struct. Mol. Biol. 2004, 11:358-364.
28. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996, 382:325-331.
29. Sia S.K., Carr P.A., Cochran A.G., Malashkevich V.N., Kim P.S. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA 2002, 99:14664-14669.
30. Discovery Studio, version 2.0; Accelrys: San Diego, CA, 2007.
31. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
32. Okuyama M., Laman H., Kingsbury S.R., Visintin C., Leo E., Eward K.L., et al. Small-molecule mimics of an α-helix for efficient transport of proteins into cells. Nat. Methods 2007, 4:153-159.
33. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720.
34. Kip1. Genes Dev. 1997, 11:1464-1478.